Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
The invention provides a pharmaceutical composition comprising an aldose reductase inhibitory 1'substituted-spiro[pyrrolidine-3,3'-indoline]-2,2',5-trione of the formula: ##STR1## wherein Ra is (2-7C)alkyl or (3-7C)alkenyl, naphthylmethyl or cinnamyl optionally bearing one or two halogeno nuclear substituents, or Ra is benzyl optionally bearing one or two substituents and benzene ring A optionally bears one or two substituents, trifluoromethyl and nitro; or a salt thereof with a base affording a pharmaceutically acceptable cation; or a non-toxic, biodegradable precursor thereof; together with a pharmaceutically acceptable diluent or carrier. The invention also provides novel compounds of formula I and processes for their manufacture.
The compositions are of application in the treatment or prophylaxis of the side effects of diabetes or galactosemia.
patent: 4177230 (1978-09-01), Sarges
patent: 4307108 (1981-12-01), Belletire
H. Schaefer, Archiv. der Pharmazie (Weinheim), 1970, 303, 183-191; Chem. Abstracts, 1970, 73:3739.
Brittain David R.
Ceperley Mary E.
Daus Donald G.
Imperial Chemical Industries plc
1'-Substituted-spiro[pyrrolidine-3,3'-indoline]-2,2',5-triones does not yet have a rating. At this time, there are no reviews or comments for this patent.If you have personal experience with 1'-Substituted-spiro[pyrrolidine-3,3'-indoline]-2,2',5-triones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1'-Substituted-spiro[pyrrolidine-3,3'-indoline]-2,2',5-triones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1184190